Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series.

Vos R, Wuyts WA, Gheysens O, Goffin KE, Schaevers V, Verleden SE, Van Herck A, Sacreas A, Heigl T, McDonough JE, Yserbyt J, Godinas L, Dupont LJ, Neyrinck AP, Van Raemdonck DE, Verbeken EK, Vanaudenaerde BM, Verleden GM.

Am J Transplant. 2018 Jul 18. doi: 10.1111/ajt.15019. [Epub ahead of print]

PMID:
30019840
2.

A role for telomere length and chromosomal damage in idiopathic pulmonary fibrosis.

McDonough JE, Martens DS, Tanabe N, Ahangari F, Verleden SE, Maes K, Verleden GM, Kaminski N, Hogg JC, Nawrot TS, Wuyts WA, Vanaudenaerde BM.

Respir Res. 2018 Jul 9;19(1):132. doi: 10.1186/s12931-018-0838-4.

3.

Clinical behaviour of patients exposed to organic dust and diagnosed with idiopathic pulmonary fibrosis.

De Sadeleer LJ, Verleden SE, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, Nemery B, Verleden GM, Hermans F, Vanaudenaerde BM, Wuyts WA.

Respirology. 2018 Jun 13. doi: 10.1111/resp.13342. [Epub ahead of print]

PMID:
29897160
4.

The aging lung: tissue telomere shortening in health and disease.

Everaerts S, Lammertyn EJ, Martens DS, De Sadeleer LJ, Maes K, van Batenburg AA, Goldschmeding R, van Moorsel CHM, Dupont LJ, Wuyts WA, Vos R, Gayan-Ramirez G, Kaminski N, Hogg JC, Janssens W, Verleden GM, Nawrot TS, Verleden SE, McDonough JE, Vanaudenaerde BM.

Respir Res. 2018 May 11;19(1):95. doi: 10.1186/s12931-018-0794-z.

5.

Cholesterol metabolism promotes B-cell positioning during immune pathogenesis of chronic obstructive pulmonary disease.

Jia J, Conlon TM, Sarker RS, Taşdemir D, Smirnova NF, Srivastava B, Verleden SE, Güneş G, Wu X, Prehn C, Gao J, Heinzelmann K, Lintelmann J, Irmler M, Pfeiffer S, Schloter M, Zimmermann R, Hrabé de Angelis M, Beckers J, Adamski J, Bayram H, Eickelberg O, Yildirim AÖ.

EMBO Mol Med. 2018 May;10(5). pii: e8349. doi: 10.15252/emmm.201708349.

6.

Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.

Ruttens D, Verleden SE, Demeyer H, Van Raemdonck DE, Yserbyt J, Dupont LJ, Vanaudenaerde BM, Vos R, Verleden GM.

PLoS One. 2018 Apr 6;13(4):e0193564. doi: 10.1371/journal.pone.0193564. eCollection 2018.

7.

Analysis of airway pathology in COPD using a combination of computed tomography, micro-computed tomography and histology.

Tanabe N, Vasilescu DM, Kirby M, Coxson HO, Verleden SE, Vanaudenaerde BM, Kinose D, Nakano Y, Paré PD, Hogg JC.

Eur Respir J. 2018 Feb 14;51(2). pii: 1701245. doi: 10.1183/13993003.01245-2017. Print 2018 Feb.

PMID:
29444912
8.

Immediate post-operative broncho-alveolar lavage IL-6 and IL-8 are associated with early outcomes after lung transplantation.

Verleden SE, Martens A, Ordies S, Neyrinck AP, Van Raemdonck DE, Verleden GM, Vanaudenaerde BM, Vos R.

Clin Transplant. 2018 Apr;32(4):e13219. doi: 10.1111/ctr.13219. Epub 2018 Feb 23.

PMID:
29405435
9.

The histomorphological spectrum of restrictive chronic lung allograft dysfunction and implications for prognosis.

von der Thüsen JH, Vandermeulen E, Vos R, Weynand B, Verbeken EK, Verleden SE.

Mod Pathol. 2018 May;31(5):780-790. doi: 10.1038/modpathol.2017.180. Epub 2018 Jan 12.

PMID:
29327719
10.

Prevention of chronic rejection after lung transplantation.

Van Herck A, Verleden SE, Vanaudenaerde BM, Verleden GM, Vos R.

J Thorac Dis. 2017 Dec;9(12):5472-5488. doi: 10.21037/jtd.2017.11.85. Review.

11.

Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.

Verleden SE, Vanaudenaerde BM, Emonds MP, Van Raemdonck DE, Neyrinck AP, Verleden GM, Vos R.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701248. doi: 10.1183/13993003.01248-2017. Print 2017 Nov.

PMID:
29146602
12.

Chronic lung allograft dysfunction phenotypes and treatment.

Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM.

J Thorac Dis. 2017 Aug;9(8):2650-2659. doi: 10.21037/jtd.2017.07.81. Review.

13.

Solid Organ Transplantation in Sarcoidosis.

Yserbyt J, Wuyts WA, Verleden SE, Verleden GM, Van Raemdonck DE, Verbeken EK, Vanaudenaerde BM, Vos R.

Semin Respir Crit Care Med. 2017 Aug;38(4):538-545. doi: 10.1055/s-0037-1602383. Epub 2017 Jul 27. No abstract available.

PMID:
28750467
14.

An optimized non-destructive protocol for testing mechanical properties in decellularized rabbit trachea.

Den Hondt M, Vanaudenaerde BM, Maughan EF, Butler CR, Crowley C, Verbeken EK, Verleden SE, Vranckx JJ.

Acta Biomater. 2017 Sep 15;60:291-301. doi: 10.1016/j.actbio.2017.07.035. Epub 2017 Jul 21.

PMID:
28739545
15.

Immunoregulatory effects of multipotent adult progenitor cells in a porcine ex vivo lung perfusion model.

Martens A, Ordies S, Vanaudenaerde BM, Verleden SE, Vos R, Van Raemdonck DE, Verleden GM, Roobrouck VD, Claes S, Schols D, Verbeken E, Verfaillie CM, Neyrinck AP.

Stem Cell Res Ther. 2017 Jul 5;8(1):159. doi: 10.1186/s13287-017-0603-5.

16.

CT-Based Local Distribution Metric Improves Characterization of COPD.

Hoff BA, Pompe E, Galbán S, Postma DS, Lammers JJ, Ten Hacken NHT, Koenderman L, Johnson TD, Verleden SE, de Jong PA, Mohamed Hoesein FAA, van den Berge M, Ross BD, Galbán CJ.

Sci Rep. 2017 Jun 7;7(1):2999. doi: 10.1038/s41598-017-02871-1.

17.

A retrospective database analysis to evaluate the potential of ex vivo lung perfusion to recruit declined lung donors.

Martens A, Van Raemdonck DE, Smits J, Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM, Degezelle K, Desschans B, Neyrinck AP.

Transpl Int. 2017 Oct;30(10):1002-1010. doi: 10.1111/tri.12990. Epub 2017 Jul 13.

PMID:
28556538
18.

A porcine ex vivo lung perfusion model with maximal argon exposure to attenuate ischemia-reperfusion injury.

Martens A, Ordies S, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM, Verbeken EK, Van Raemdonck DE, Claes S, Schols D, Chalopin M, Katz I, Farjot G, Neyrinck AP.

Med Gas Res. 2017 Mar 30;7(1):28-36. doi: 10.4103/2045-9912.202907. eCollection 2017 Jan-Mar.

19.

The Effect of Immunosuppression on Airway Integrity.

Bellon H, Vandermeulen E, Verleden SE, Heigl T, Vriens H, Lammertyn E, Verlinden L, Vanhove T, Verstuyf M, Hoet P, Vos R, Verleden GM, Vanaudenaerde BM.

Transplantation. 2017 Dec;101(12):2855-2861. doi: 10.1097/TP.0000000000001809.

PMID:
28471870
20.

Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.

Leyssens A, Dierickx D, Verbeken EK, Tousseyn T, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verleden GM, Van Raemdonck DE, Vos R.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12983. Epub 2017 May 8.

PMID:
28383790
21.

High-dose vitamin D after lung transplantation: A randomized trial.

Vos R, Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Van Herck A, Sacreas A, Heigl T, Schaevers V, Van Raemdonck DE, Verbeken EK, Neyrinck AP, Dupont LJ, Yserbyt J, Vanaudenaerde BM, Verleden GM.

J Heart Lung Transplant. 2017 Aug;36(8):897-905. doi: 10.1016/j.healun.2017.03.008. Epub 2017 Mar 8.

PMID:
28365177
22.

"White-Out" After Lung Transplantation: A Multicenter Cohort Description of Late Acute Graft Failure.

Verleden SE, Gottlieb J, Dubbeldam A, Verleden GM, Suhling H, Welte T, Vos R, Greer M.

Am J Transplant. 2017 Jul;17(7):1905-1911. doi: 10.1111/ajt.14268. Epub 2017 Apr 11.

23.

Radiological Analysis of Unused Donor Lungs: A Tool to Improve Donor Acceptance for Transplantation?

Verleden SE, Martens A, Ordies S, Heigl T, Bellon H, Vandermeulen E, Van Herck A, Sacreas A, Verschakelen J, Coudyzer W, Van Raemdonck DE, Vos R, Weynand B, Verleden GM, Vanaudenaerde B, Neyrinck A.

Am J Transplant. 2017 Jul;17(7):1912-1921. doi: 10.1111/ajt.14255. Epub 2017 Mar 30.

24.

Short- and Long-term Outcomes After Lung Transplantation From Circulatory-Dead Donors: A Single-Center Experience.

Ruttens D, Martens A, Ordies S, Verleden SE, Neyrinck AP, Vos R, Boada MC, Vanaudenaerde BM, Verleden GM, Van Raemdonck D.

Transplantation. 2017 Nov;101(11):2691-2694. doi: 10.1097/TP.0000000000001678.

PMID:
28207629
25.

Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options.

Bellon H, Vandermeulen E, Mathyssen C, Sacreas A, Verleden SE, Heigl T, Vriens H, Lammertyn E, Pilette C, Hoet P, Vos R, Vanaudenaerde BM, Verleden GM.

Transpl Int. 2017 Apr;30(4):388-397. doi: 10.1111/tri.12915. Epub 2017 Mar 2.

26.

End-stage cystic fibrosis lung disease is characterised by a diverse inflammatory pattern: an immunohistochemical analysis.

Lammertyn EJ, Vandermeulen E, Bellon H, Everaerts S, Verleden SE, Van Den Eynde K, Bracke KR, Brusselle GG, Goeminne PC, Verbeken EK, Vanaudenaerde BM, Dupont LJ.

Respir Res. 2017 Jan 10;18(1):10. doi: 10.1186/s12931-016-0489-2.

27.

Immunological diversity in phenotypes of chronic lung allograft dysfunction: a comprehensive immunohistochemical analysis.

Vandermeulen E, Lammertyn E, Verleden SE, Ruttens D, Bellon H, Ricciardi M, Somers J, Bracke KR, Van Den Eynde K, Tousseyn T, Brusselle GG, Verbeken EK, Verschakelen J, Emonds MP, Van Raemdonck DE, Verleden GM, Vos R, Vanaudenaerde BM.

Transpl Int. 2017 Feb;30(2):134-143. doi: 10.1111/tri.12882. Epub 2016 Dec 8.

28.

Restrictive allograft syndrome after lung transplantation: new radiological insights.

Dubbeldam A, Barthels C, Coolen J, Verschakelen JA, Verleden SE, Vos R, Verleden GM, De Wever W.

Eur Radiol. 2017 Jul;27(7):2810-2817. doi: 10.1007/s00330-016-4643-5. Epub 2016 Nov 22.

PMID:
27878373
29.

Nondestructive cryomicro-CT imaging enables structural and molecular analysis of human lung tissue.

Vasilescu DM, Phillion AB, Tanabe N, Kinose D, Paige DF, Kantrowitz JJ, Liu G, Liu H, Fishbane N, Verleden SE, Vanaudenaerde BM, Lenburg M, Stevenson CS, Spira A, Cooper JD, Hackett TL, Hogg JC.

J Appl Physiol (1985). 2017 Jan 1;122(1):161-169. doi: 10.1152/japplphysiol.00838.2016. Epub 2016 Nov 17.

30.

An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe.

Ruttens D, Verleden SE, Bijnens EM, Winckelmans E, Gottlieb J, Warnecke G, Meloni F, Morosini M, Van Der Bij W, Verschuuren EA, Sommerwerck U, Weinreich G, Kamler M, Roman A, Gomez-Olles S, Berastegui C, Benden C, Holm AM, Iversen M, Schultz HH, Luijk B, Oudijk EJ, Kwakkel-van Erp JM, Jaksch P, Klepetko W, Kneidinger N, Neurohr C, Corris P, Fisher AJ, Lordan J, Meachery G, Piloni D, Vandermeulen E, Bellon H, Hoffmann B, Vienneau D, Hoek G, de Hoogh K, Nemery B, Verleden GM, Vos R, Nawrot TS, Vanaudenaerde BM.

Eur Respir J. 2017 Jan 18;49(1). pii: 1600484. doi: 10.1183/13993003.00484-2016. Print 2017 Jan.

31.

Steroids can reduce warm ischemic reperfusion injury in a porcine donation after circulatory death model with ex vivo lung perfusion evaluation.

Martens A, Boada M, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM, Verbeken EK, Van Raemdonck D, Schols D, Claes S, Neyrinck AP.

Transpl Int. 2016 Nov;29(11):1237-1246. doi: 10.1111/tri.12823.

32.

Parametric Response Mapping of Bronchiolitis Obliterans Syndrome Progression After Lung Transplantation.

Verleden SE, Vos R, Vandermeulen E, Ruttens D, Bellon H, Heigl T, Van Raemdonck DE, Verleden GM, Lama V, Ross BD, Galbán CJ, Vanaudenaerde BM.

Am J Transplant. 2016 Nov;16(11):3262-3269. doi: 10.1111/ajt.13945. Epub 2016 Jul 29.

33.

Phenotypes of Chronic Lung Allograft Dysfunction: Getting Closer Step by Step?

Verleden SE, Vanaudenaerde BM, Vos R, Verleden GM.

Am J Transplant. 2016 Nov;16(11):3071-3072. doi: 10.1111/ajt.13921. Epub 2016 Jul 13. No abstract available.

34.

Parametric Response Mapping as an Imaging Biomarker in Lung Transplant Recipients.

Belloli EA, Degtiar I, Wang X, Yanik GA, Stuckey LJ, Verleden SE, Kazerooni EA, Ross BD, Murray S, Galbán CJ, Lama VN.

Am J Respir Crit Care Med. 2017 Apr 1;195(7):942-952. doi: 10.1164/rccm.201604-0732OC.

35.

The role of recipient derived interleukin-17A in a murine orthotopic lung transplant model of restrictive chronic lung allograft dysfunction.

Yamada Y, Vandermeulen E, Heigl T, Somers J, Vaneylen A, Verleden SE, Bellon H, De Vleeschauwer S, Verbeken EK, Van Raemdonck DE, Vos R, Verleden GM, Jungraithmayr W, Vanaudenaerde BM.

Transpl Immunol. 2016 Nov;39:10-17. doi: 10.1016/j.trim.2016.10.001. Epub 2016 Oct 11.

PMID:
27737799
36.

Thin-Section CT Features of Idiopathic Pulmonary Fibrosis Correlated with Micro-CT and Histologic Analysis.

Mai C, Verleden SE, McDonough JE, Willems S, De Wever W, Coolen J, Dubbeldam A, Van Raemdonck DE, Verbeken EK, Verleden GM, Hogg JC, Vanaudenaerde BM, Wuyts WA, Verschakelen JA.

Radiology. 2017 Apr;283(1):252-263. doi: 10.1148/radiol.2016152362. Epub 2016 Oct 6.

37.

Humoral immunity in phenotypes of chronic lung allograft dysfunction: A broncho-alveolar lavage fluid analysis.

Vandermeulen E, Verleden SE, Bellon H, Ruttens D, Lammertyn E, Claes S, Vandooren J, Ugarte-Berzal E, Schols D, Emonds MP, Van Raemdonck DE, Opdenakker G, Verleden GM, Vos R, Vanaudenaerde BM.

Transpl Immunol. 2016 Sep;38:27-32. doi: 10.1016/j.trim.2016.08.004. Epub 2016 Aug 22.

PMID:
27561239
38.

Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation.

Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Dubbeldam A, De Wever W, Dupont LJ, Van Raemdonck DE, Vanaudenaerde BM, Verleden GM, Benden C, Vos R.

J Heart Lung Transplant. 2016 Sep;35(9):1078-84. doi: 10.1016/j.healun.2016.03.022. Epub 2016 Apr 16.

PMID:
27212563
39.

Advances in Understanding Bronchiolitis Obliterans After Lung Transplantation.

Verleden SE, Sacreas A, Vos R, Vanaudenaerde BM, Verleden GM.

Chest. 2016 Jul;150(1):219-25. doi: 10.1016/j.chest.2016.04.014. Epub 2016 May 20. Review.

PMID:
27212132
40.

Morphometric Analysis of Explant Lungs in Cystic Fibrosis.

Boon M, Verleden SE, Bosch B, Lammertyn EJ, McDonough JE, Mai C, Verschakelen J, Kemner-van de Corput M, Tiddens HA, Proesmans M, Vermeulen FL, Verbeken EK, Cooper J, Van Raemdonck DE, Decramer M, Verleden GM, Hogg JC, Dupont LJ, Vanaudenaerde BM, De Boeck K.

Am J Respir Crit Care Med. 2016 Mar 1;193(5):516-26. doi: 10.1164/rccm.201507-1281OC.

PMID:
26551917
41.

CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients.

Vercauteren IM, Verleden SE, McDonough JE, Vandermeulen E, Ruttens D, Lammertyn EJ, Bellon H, De Dycker E, Dooms C, Yserbyt J, Verleden GM, Vanaudenaerde BM, Wuyts WA.

Exp Lung Res. 2015;41(8):459-65. doi: 10.3109/01902148.2015.1073407.

PMID:
26381718
42.

Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.

Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Vanaudenaerde BM, Somers J, Schoonis A, Schaevers V, Van Raemdonck DE, Neyrinck A, Dupont LJ, Yserbyt J, Verleden GM, Vos R.

Am J Transplant. 2016 Jan;16(1):254-61. doi: 10.1111/ajt.13417. Epub 2015 Aug 4.

43.

Chronic lung allograft dysfunction: evolving practice.

Vos R, Verleden SE, Verleden GM.

Curr Opin Organ Transplant. 2015 Oct;20(5):483-91. doi: 10.1097/MOT.0000000000000236. Review.

PMID:
26262458
44.

BAL neutrophilia in azithromycin-treated lung transplant recipients: Clinical significance.

Vandermeulen E, Verleden SE, Ruttens D, Moelants E, Mortier A, Somers J, Bellon H, Piloni D, Dupont LJ, Van Raemdonck DE, Proost P, Schols D, Vos R, Verleden GM, Vanaudenaerde BM.

Transpl Immunol. 2015 Sep;33(1):37-44. doi: 10.1016/j.trim.2015.07.001. Epub 2015 Jul 11.

PMID:
26168736
45.

Linking clinical phenotypes of chronic lung allograft dysfunction to changes in lung structure.

Verleden SE, Vasilescu DM, McDonough JE, Ruttens D, Vos R, Vandermeulen E, Bellon H, Geenens R, Verbeken EK, Verschakelen J, Van Raemdonck DE, Wuyts WA, Sokolow Y, Knoop C, Cooper JD, Hogg JC, Verleden GM, Vanaudenaerde BM.

Eur Respir J. 2015 Nov;46(5):1430-9. doi: 10.1183/09031936.00010615. Epub 2015 Jun 25.

46.

Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study.

Verleden SE, Todd JL, Sato M, Palmer SM, Martinu T, Pavlisko EN, Vos R, Neyrinck A, Van Raemdonck D, Saito T, Oishi H, Keshavjee S, Greer M, Warnecke G, Gottlieb J, Haverich A.

Am J Transplant. 2015 Aug;15(8):2223-30. doi: 10.1111/ajt.13281. Epub 2015 Apr 30.

47.

Interleukin-17 receptor polymorphism predisposes to primary graft dysfunction after lung transplantation.

Somers J, Ruttens D, Verleden SE, Vandermeulen E, Piloni D, Wauters E, Lambrechts D, Vos R, Verleden GM, Vanaudenaerde B, van Raemdonck DE.

J Heart Lung Transplant. 2015 Jul;34(7):941-9. doi: 10.1016/j.healun.2015.03.009. Epub 2015 Mar 26.

PMID:
25935436
48.

Role of genetics in lung transplant complications.

Ruttens D, Vandermeulen E, Verleden SE, Bellon H, Vos R, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden GM.

Ann Med. 2015 Mar;47(2):106-15. doi: 10.3109/07853890.2015.1004359. Epub 2015 Mar 13. Review.

PMID:
25766881
49.

Restrictive chronic lung allograft dysfunction: Where are we now?

Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden G, Vos R.

J Heart Lung Transplant. 2015 May;34(5):625-30. doi: 10.1016/j.healun.2014.11.007. Epub 2014 Nov 11.

PMID:
25577564
50.

Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation.

Vos R, Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Neyrinck A, Van Raemdonck DE, Yserbyt J, Dupont LJ, Verbeken EK, Moelants E, Mortier A, Proost P, Schols D, Cox B, Verleden GM, Vanaudenaerde BM.

Am J Transplant. 2014 Dec;14(12):2736-48. doi: 10.1111/ajt.12942. Epub 2014 Nov 13.

Supplemental Content

Loading ...
Support Center